Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Her-2 Negative Unresectable Locally Advanced Gastric Cancer: a National Multicenter Randomized Controlled Study
Latest Information Update: 29 Aug 2023
At a glance
- Drugs Envafolimab (Primary) ; Fruquintinib (Primary) ; Oxaliplatin (Primary) ; Tegafur (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
Most Recent Events
- 23 Aug 2023 Planned initiation date changed from 1 Jul 2023 to 1 Sep 2023.
- 26 Jun 2023 New trial record